ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB393

Metformin Attenuates Oxidative Stress and Inflammatory Responses in Obesity-Associated Nonalcoholic Fatty Liver Disease (NAFLD)

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Sharma, Amod, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
  • Hakkak, Reza, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
  • Gokden, Neriman, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
  • Parajuli, Nirmala, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
Background

Chronic kidney disease (CKD) is significantly more prevalent in individuals with obesity-associated non-alcoholic fatty liver disease (Ob-NAFLD), yet the mechanisms linking these conditions remain poorly understood. This study investigates the renal consequences of Ob-NAFLD and evaluates the potential protective effects of metformin, a widely used antidiabetic drug with emerging therapeutic value in NAFLD.

Methods

Five-week-old female Zucker rats (obese fa/fa and lean Fa/Fa) were fed a standard diet for 8 weeks to induce obesity NAFLD (Ob-NAFLD) followed by oral treatment with metformin (1 g/kg food, ad libitum) for 10 weeks. Kidneys were harvested and analyzed histologically and biochemically.

Results

Ob-NAFLD rats showed significant renal damage, including tubular injury, mesangial expansion, and fibrosis compared to lean rats. Similarly, Ob-NAFLD rats showed elevated macrophage and neutrophil infiltration, upregulated inflammatory genes (TNF-α and CCL2), and increased markers of mitochondrial fission (DRP1 and phospho-DRP1), oxidative stress (nitrotyrosine, p22phox), and apoptosis (caspase-3), compared to lean group. Low dose oral metformin treatment significantly reduced inflammation (TNF-α) and oxidative stress (nitrotyrosine) but was inadequate to preserve renal morphology in rat kidneys with Ob-NAFLD.

Conclusion

Altogether, these findings suggest that Ob-NAFLD drives CKD via inflammation and oxidative/mitochondrial stress. While metformin offers anti-inflammatory and antioxidant benefits, longer treatment or combination therapies may be needed for renal protection.

Funding: Arkansas Bioscience Institute (Hakkak) and R01DK123264 (Parajuli).

Funding

  • NIDDK Support

Digital Object Identifier (DOI)